7149-42-0

Basic information

• Product Name: (1-METHYL-4-PIPERIDINYL)METHANAMINE
• Synonyms: TIMTEC-BB SBB009719;(1-METHYL-4-PIPERIDINYL)METHANAMINE;(1-METHYLPIPERIDIN-4-YL)METHANAMINE;[(1-METHYLPIPERIDIN-4-YL)METHYL]AMINE;1-METHYL-PIPERIDIN-4-METHYLAMINE;AKOS B025002;4-AMINOMETHYL-1-METHYLPIPERIDINE;BUTTPARK 145\06-16
• CAS NO: 7149-42-0
• Molecular Formula: C₇H₁₆N₂
• Molecular Weight: 128.22
• EINECS: 230-477-2
• Product Categories: Aminomethyl's;Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines;C5 to C9;Building Blocks;C5 to C7;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;New Products for Chemical Synthesis;Piperidines
• Mol File: 7149-42-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 0°C
• Boiling Point: 80 °C
• Flash Point: 0°C
• Appearance: /
• Density: 0.901g/cm³
• Vapor Pressure: 2.47mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 10.13±0.29(Predicted)
• CAS DataBase Reference: (1-METHYL-4-PIPERIDINYL)METHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (1-METHYL-4-PIPERIDINYL)METHANAMINE(7149-42-0)
• EPA Substance Registry System: (1-METHYL-4-PIPERIDINYL)METHANAMINE(7149-42-0)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-20/22-22-10
• Safety Statements: 26-36/37/39-45-23
• RIDADR: 2735
• WGK Germany: 1
• HazardClass: IRRITANT
• Hazardous Substances Data: 7149-42-0(Hazardous Substances Data)

Usage

Chemical Properties

Colourless liquid

Uses

(1-methyl-4-piperidinyl)methanamine is a reagent used in the synthesis of novel indole-carboxamides which are inhibitors of neurotropic alphavirus.

InChI:InChI=1/C7H16N2/c1-9-4-2-7(6-8)3-5-9/h7H,2-6,8H2,1H3

Upstream product

• 39546-32-2 4-carboxamidopiperidine 
• 62718-28-9 1-methylpiperidine-4-carboxamide 
• 20691-92-3 1-methylpiperidine-4-carbonitrile 

Downstream Products

• 1313732-39-6 [3-(3-dimethylamino-phenyl)-6-methyl-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-5-yl]-(1-methyl-piperidin-4-ylmethyl)-amine 
• 1313732-37-4 (1-methyl-piperidin-4-ylmethyl)-[6-methyl-3-(3-trifluoromethyl-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-5-yl]-amine 
• 1313732-36-3 3-{6-methyl-5-[(1-methyl-piperidin-4-ylmethyl)-amino]-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-3-yl}-benzonitrile 
• 1313732-42-1 (1-methyl-piperidin-4-ylmethyl)-[3-(3-trifluoromethoxy-phenyl)-7,8,9,10-tetrahydro-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine 
• 1313732-87-4 (1-methyl-piperidin-4-ylmethyl)-[8,8,9-trimethyl-3-(3-trifluoromethoxy-phenyl)-8,9-dihydro-7H-6-oxa-1,2,3a,4,9-pentaaza-cyclopenta[a]naphthalen-5-yl]-amine 
• 1313732-88-5 (1-methyl-piperidin-4-ylmethyl)-[6,7,7-trimethyl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-5-yl]-amine 
• 1313732-45-4 [6,7-dimethyl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-5-yl]-(1-methyl-piperidin-4-ylmethyl)-amine 
• 1313732-18-1 [9-ethyl-3-(3-trifluoromethoxy-phenyl)-8,9-dihydro-7H-6-oxa-1,2,3a,4,9-pentaaza-cyclopenta[a]naphthalen-5-yl]-(1-methyl-piperidin-4-ylmethyl)-amine 
• 1313732-17-0 [6-ethyl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-5-yl]-(1-methyl-piperidin-4-ylmethyl)-amine 
• 1313732-21-6 (1-methyl-piperidin-4-ylmethyl)-[6-methyl-3-(3-trifluoromethoxy-phenyl)-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-5-yl]-amine 
• 1313732-22-7 (1-methyl-piperidin-4-ylmethyl)-[9-methyl-3-(3-trifluoromethoxy-phenyl)-8,9-dihydro-7H-6-oxa-1,2,3a,4,9-pentaaza-cyclopenta[a]naphthalen-5-yl]-amine 
• 1313732-06-7 [3-(4-methoxy-phenyl)-6-methyl-7,8-dihydro-6H-9-oxa-1,2,3a,4,6-pentaaza-cyclopenta[a]naphthalen-5-yl]-(1-methyl-piperidin-4-ylmethyl)-amine 
• 1266620-20-5 C₁₅H₁₉ClFN₃O₂ 
• 1089672-70-7 C₂₇H₃₄N₆O₂ 

Relevant articles and documents

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

The COVID-19 pandemic has been disastrous to society and effective drugs are urgently needed. The papain-like protease domain (PLpro) of SARS-CoV-2 (SCoV2) is indispensable for viral replication and represents a putative target for pharmacological intervention. In this work, we describe the development of a potent and selective SCoV2 PLpro inhibitor, 19. The inhibitor not only effectively blocks substrate cleavage and immunosuppressive function imparted by PLpro, but also markedly mitigates SCoV2 replication in human cells, with a submicromolar IC50. We further present a convenient and sensitive activity probe, 7, and complementary assays to readily evaluate SCoV2 PLpro inhibitors in vitro or in cells. In addition, we disclose the co-crystal structure of SCoV2 PLpro in complex with a prototype inhibitor, which illuminates their detailed binding mode. Overall, these findings provide promising leads and important tools for drug discovery aiming to target SCoV2 PLpro.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Indazole derivatives having monocyclic amine

An indazole compound having the formula (I): wherein: R1 is hydrogen, C1 -C6 alkyl, C3 -C6 alkenyl or C3 -C6 cycloalkyl; Q is carbonyl, thiocarbonyl or methylene; and R2 is a group of the formula (II) or (IV); STR1 wherein R1 is C1 -C6 alkyl, C3 -C6 alkenyl or benzyl, of which a phenyl group thereof is optionally mono- or di-substituted by the same or different halogen or methoxy; m is 0 to 2; n and o is 1 or 2. The compound exhibits 5-HT4 receptor agonist activity.